

QPS

QPS is an independent, global player in the field of contract research, with facilities in the USA, the Netherlands, India and Taiwan engaging more than 750 qualified and experienced professionals. Our key competence areas are drug metabolism and pharmacokinetics, toxicology, bioanalysis, translational medicine, and early stage and phase 2 – 4 clinical research (www.qps.com).

Full Service Provider

Over the past two decades, QPS has performed thousands of preclinical and clinical studies for local and international pharmaceutical and biotechnology companies, covering numerous disease therapies. QPS provides one of the largest capacities in bioanalysis for small molecules and biologics, as well as specialized biomarker assay capabilities.


Our early stage clinical research facilities comprise 400 phase I beds (Netherlands: 24, Taiwan: 40, India: 92, USA: 240). Over the past 15 years, QPS phase I sites have collectively completed more than a thousand clinical trials involving tens of thousands of study volunteers. For late stage clinical research, QPS has access to a worldwide network of clinicians who provide phase 2, 3 and 4 clinical research services in combination with pharmacometrics services such as data management, biostatistics, PK/PD evaluation and medical writing.

Dedicated Framework of Integrated Pain Research Services

Ethic Recently, QPS has extended its service portfolio by adding more pain research facilities and expertise. For phase 1 and 2a investigations of both nociceptive and neuropathic pain, the Quantitative Sensory Testing Battery (QST) and the Third Molar Extraction Model (M3) are available. In the QST battery, cold/heat and mechanical/pressure thresholds are measured in healthy volunteers to investigate pain/flare and primary/secondary hyperalgesia.

The M3 model is performed in collaboration with the Department of Orofacial Surgery of the University Medical Center Groningen in the Netherlands, a large facility that provides easy subject recruitment and high recruitment rates. Both pain and anti-inflammatory biomarkers can be measured on request. Especially the combination of both pain models in the same person who needs M3 surgery twice on different sites offers the opportunity to investigate a nociceptive and anti-hyperalgesic effect simultaneously.

QPS manages a network of pain clinicians in both university and non-university hospitals through which we may either mediate or conduct phase 2b and 3 pain studies. Via its dedicated framework of integrated pain research services, QPS offers a full range of outsourcing solutions from 'first in human' to 'first in patient' (proof of concept) to late stage pain studies.



CONTACTS:

Pim (W.J.) Meijler, MD, PhD
Pain Expert, Senior Medical Adviser
Pim.Meijler@qps.com

Business Development
BusinessDevelopment@qps.com
www.qps.com

QPS Netherlands B.V. Petrus Campersingel 123
NL-9713 AG Groningen, The Netherlands
Tel. +31 (0)50 3048000 Fax. +31 (0)50 3048001